Key takeaways for Indiana
- • No GLP-1 is FDA-approved for PCOS — entirely off-label.
- • BMI 27+ may qualify under standard Wegovy/Zepbound labels if comorbidities present.
- • Improvements seen in insulin resistance, weight, and androgens; fertility data limited.
- • Healthy Indiana Plan / Hoosier Healthwise coverage rules apply for PCOS (Polycystic Ovary Syndrome) patients in Indiana — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for PCOS (Polycystic Ovary Syndrome)
No GLP-1 is FDA-approved specifically for PCOS. However, small randomized trials and observational studies show GLP-1 RAs improve insulin sensitivity, support 5-15% weight loss, reduce free testosterone, and may improve menstrual regularity and ovulation. Evidence grade: C-B (smaller trials, growing evidence base). PCOS guidelines (ESHRE/Monash 2023) recognize obesity-targeted pharmacotherapy as adjunct. Patients trying to conceive should stop GLP-1s at least 2 months before pregnancy attempts.
Indiana-specific context
Indiana has telehealth access concentrated in Indianapolis, Fort Wayne, Evansville metros, with additional reach to South Bend and Carmel. Indiana University Health, Community Health Network is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.in.gov/health.
Indianatelehealth & pricing rules
- • Indiana permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Indiana allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Indiana: ~$235/mo (compounded options often lower, brand higher).